Skip to content

Different Concentrations of Bupivacaine in Erector Spinae Plane Block in Hip Surgeries

Comparison of the Analgesic Efficacy of Three Different Concentrations of Bupivacaine in Ultrasound Guided Erector Spinae Plane Block in Hip Surgeries: Randomized Control Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04442750
Enrollment
100
Registered
2020-06-23
Start date
2020-06-22
Completion date
2020-11-01
Last updated
2020-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

The prevalence of hip replacement surgery is increasing nowadays. Patients are usually older age and suffer from comorbidities may be an anesthetic and analgesic challenge. Erector spinae plane block (ESPB) is a newly described technique that is has been demonstrated in previous studies for chronic and acute pain treatment. The exact volume and concentration of local anesthetic (LA) to be used in ESPB is not well established.

Detailed description

Aim of the work is to compare the analgesic effects of three different concentrations of the same volume of local anesthetics; 30 ml of 0.50% vs 0.375% vs 0.25% bupivacaine in patients undergoing hip surgeries. Prospective randomized double blinded study that will be conducted in at Kasr El-Ainy hospital orthopedic surgical theater. patients, undergoing hip surgeries will be randomly allocated into three equal groups, each (n=44), using computerized generated random tables 1. Group F: 44 patients will receive single shot erector spinae block at the level of L4 with 30 ml 0.50% bupivacaine. 2. Group M: 44 patients will receive single shot erector spinae block at the level of L4 with 30 ml 0.375% bupivacaine. 3. Group H: 44 patients will receive single shot of erector spinae block at the level of L4with 30ml 0.25% bupivacaine .

Interventions

The patient will be placed in Lateral Decubitus with a surgical side upwards. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will be then rotated into a longitudinal orientation 2-3 cm lateral to vertebral column. The lumbar skin region will be sterilized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex A'; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a cranial-to-caudal direction until contact will made with the L4 transverse process. Local anesthetic solution will be injected and its type will be selected according to the studied group and patients were placed in a supine position and general anesthesia will be started.

PROCEDUREGeneral anesthesia

Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium. Anaesthesia will be maintained with inhaled sevoflurane 1-1.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium o.1 m\\kg will be provided every 30 minutes. Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of baseline levels. At the end of surgery, residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and will extubation be performed after complete recovery of the airway reflexes.

The patient will receive 30ml bupivacain 0.5% in erector spinae block

DRUGBupivacaine 0.375%

The patient will receive 30ml bupivacain 0.375% in erector spinae block

DRUGBupivacaine 0.25%

The patient will receive 30ml bupivacain 0.25% in erector spinae block

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Both genders (Males and females). * Type of surgery; unilateral elective hip surgeries * Physical status ASA I, II. * Age ≥ 18 and ≤ 65 Years. * Body mass index (BMI): \> 20 kg/m2 and \< 35 kg/m2.

Exclusion criteria

* Patients with known sensitivity or contraindication to drug used in the study (local anesthetics, opioids). * History of psychological disorders and/or chronic pain. * Contraindication to regional anesthesia e.g. local sepsis, pre- existing peripheral neuropathies and coagulopathy. * Infection of the skin at the site of needle puncture area. * Patient refusal. * Severe respiratory or cardiac disorders. * Advanced liver or kidney disease. * Pregnancy. * Patient with surgery duration more than two hours.

Design outcomes

Primary

MeasureTime frameDescription
The total 24 hours amount of morphine consumption24 hours postoperativeThe total amount of morphine consumption in the first 24 hours postoperatively

Secondary

MeasureTime frameDescription
Total amount of intraoperative fentanyl2 hours intraoperatively
Numeric Pain Rating Scale24 hours postoperativeNumeric Pain Rating Scale, both at rest and during movement: 30 minutes,2, 4,6, 8, 12, 16, 20 and 24 hours postoperatively. The Numeric Rating Scale (NRS) is the simplest and most commonly used numeric scale in which the patient rates the pain from 0 (no pain) to 10 (worst pain).
Time for first rescue analgesia24 hours
Block related complications24 hours postoperative• Block related complications such as local anesthetic toxicity, hematoma formation and lower limb weakness.

Countries

Egypt

Contacts

Primary ContactBassant abdelhamid, M.D.
bassantmohamed197@yahoo.com01224254012

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026